73 results
8-K
EX-3.1
CELU
Celularity Inc - Ordinary Shares
24 May 19
GX Acquisition Corp. Announces Pricing of $250,000,000 Initial Public Offering
5:00pm
and to establish from time to time the number of shares to be included in each such series and to fix the voting rights, if any, designations, powers … not be by written ballot. The holders of shares of Common Stock shall not have cumulative voting rights with regard to election of directors.
Section
8-K
EX-3.1
CELU
Celularity Inc - Ordinary Shares
24 May 19
GX Acquisition Corp. Announces Pricing of $250,000,000 Initial Public Offering
5:00pm
and to establish from time to time the number of shares to be included in each such series and to fix the voting rights, if any, designations, powers … not be by written ballot. The holders of shares of Common Stock shall not have cumulative voting rights with regard to election of directors.
Section
8-K
EX-3.1
CELU
Celularity Inc - Ordinary Shares
22 Jul 21
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
4:13pm
are as follows:
1. Voting Rights. Each holder of shares of Class A Common Stock shall be entitled to one vote for each share thereof held. Except as required
S-1/A
EX-3.2
CELU
Celularity Inc - Ordinary Shares
13 May 19
IPO registration (amended)
4:55pm
and to establish from time to time the number of shares to be included in each such series and to fix the voting rights, if any, designations, powers … of directors need not be by written ballot. The holders of shares of Common Stock shall not have cumulative voting rights with regard to election
S-1
EX-3.1
dp6me7hkek 3ljbya
26 Apr 19
IPO registration
4:23pm
DRS
EX-3.1
6h5velrtj5vq0pha
5 Nov 18
Draft registration statement
12:00am
425
EX-10.3
lng227r32ucdeii
8 Jan 21
Business combination disclosure
7:02am
8-K
EX-10.3
kxqs6n 1997hy1
8 Jan 21
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
7:03am
424B5
o0j27nr0rb zku0l
28 Jul 23
Prospectus supplement for primary offering
4:24pm
424B5
dr9iamhd74v
6 Apr 23
Prospectus supplement for primary offering
9:03pm
424B3
jbvwf 9jkx
24 Aug 22
Prospectus supplement
4:54pm
S-3
5ih56z5
11 Aug 22
Shelf registration
4:29pm
PRE 14A
tjrft79t347m6gad
29 Mar 21
Preliminary proxy
7:34am
424B3
2yh9rkq52k dtfczrcpf
24 Aug 22
Prospectus supplement
4:52pm
10-K
EX-4.2
7oqqoh 6yhz
24 Mar 20
Annual report
12:00am
POS AM
6hle2
11 Aug 22
Prospectus update (post-effective amendment)
4:20pm